{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:30Z","timestamp":1789997550512,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s11912-022-01226-y","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T06:02:50Z","timestamp":1647928970000},"page":"835-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections"],"prefix":"10.1007","volume":"24","author":[{"given":"Francisco","family":"Moreno-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-9625","authenticated-orcid":false,"given":"Brenda","family":"Gomez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"issue":"8","key":"1226_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/cid\/cir492","volume":"53","author":"A Safdar","year":"2011","unstructured":"Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53(8):798\u2013806.","journal-title":"Clin Infect Dis"},{"key":"1226_CR2","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Nucci M, Anaissie EJ. Prevention of infections in patients with hematological\u00a0malignancies. Neoplast Dis Blood. 2017;1047\u201362. https:\/\/doi.org\/10.1007\/978-3-319-64263-5_49. This article describe various strategies directed to the prevention of infections in patients with hematological malignancies, according to this risk-based strategy.","DOI":"10.1007\/978-3-319-64263-5_49"},{"issue":"10","key":"1226_CR3","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.12401","volume":"13","author":"DF Florescu","year":"2013","unstructured":"Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13(10):2601\u201310.","journal-title":"Am J Transplant"},{"key":"1226_CR4","unstructured":"CDC. COVID-19 vaccines for moderately or severely immunocompromised people. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral\u00a0Diseases; 2022."},{"issue":"10","key":"1226_CR5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1086\/374784","volume":"187","author":"D Kumar","year":"2003","unstructured":"Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639\u201345.","journal-title":"J Infect Dis"},{"issue":"2","key":"1226_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1086\/318482","volume":"32","author":"EA Blumberg","year":"2001","unstructured":"Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis. 2001;32(2):307\u201310.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1226_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00277-019-03621-1","volume":"98","author":"A Brioli","year":"2019","unstructured":"\u2022 Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98(3):713\u201322 This study assess the risk factors associated with infections in the era of novel agents in myeloma patients.","journal-title":"Ann Hematol"},{"issue":"2","key":"1226_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","volume":"64","author":"GP Bodey","year":"1966","unstructured":"Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328\u201340.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1226_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archinte.1975.00330050089015","volume":"135","author":"EA Sickles","year":"1975","unstructured":"Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135(5):715\u20139.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1226_CR10","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1086\/324502","volume":"33","author":"G Engelich","year":"2001","unstructured":"Engelich G, Wright DG, Hartshorn KL. Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis. 2001;33(12):2040\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1226_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1086\/518873","volume":"45","author":"KV Rolston","year":"2007","unstructured":"Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45(2):228\u201333.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1226_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0749-0704(05)70198-6","volume":"17","author":"A Safdar","year":"2001","unstructured":"Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001;17(3):531\u201370 vii-viii.","journal-title":"Crit Care Clin"},{"issue":"11","key":"1226_CR13","first-page":"815","volume":"6","author":"KV Rolston","year":"2008","unstructured":"Rolston KV. Review: Daptomycin for the treatment of gram-positive infections in neutropenic cancer patients. Clin Adv Hematol Oncol. 2008;6(11):815\u20137.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"1226_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archinte.160.4.501","volume":"160","author":"I Chatzinikolaou","year":"2000","unstructured":"Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160(4):501\u20139.","journal-title":"Arch Intern Med"},{"issue":"Suppl 5","key":"1226_CR15","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1093\/cid\/ciu598","volume":"59 Suppl 5","author":"T Holland","year":"2014","unstructured":"Holland T, Fowler VG Jr, Shelburne SA. 3rd. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis. 2014;59 Suppl 5(Suppl 5):S331\u20134.","journal-title":"Clin Infect Dis"},{"key":"1226_CR16","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","volume":"30 Suppl 1","author":"J Klastersky","year":"2007","unstructured":"Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30 Suppl 1:S51\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1226_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cncr.20890","volume":"103","author":"NV Sipsas","year":"2005","unstructured":"Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103(6):1103\u201313.","journal-title":"Cancer."},{"issue":"Suppl 5","key":"1226_CR18","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.1093\/cid\/ciu612","volume":"59 Suppl 5","author":"F Perez","year":"2014","unstructured":"Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis. 2014;59 Suppl 5(Suppl 5):S335\u20139.","journal-title":"Clin Infect Dis"},{"key":"1226_CR19","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1086\/427330","volume":"40 Suppl 4","author":"KA Sepkowitz","year":"2005","unstructured":"Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis. 2005;40 Suppl 4:S253\u20136.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1226_CR20","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1164\/ajrccm\/143.6.1386","volume":"143","author":"NA Ettinger","year":"1991","unstructured":"Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation. Part I. Am Rev Respir Dis. 1991;143(6):1386\u2013405.","journal-title":"Am Rev Respir Dis"},{"issue":"24","key":"1226_CR21","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","volume":"338","author":"JA Fishman","year":"1998","unstructured":"Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741\u201351.","journal-title":"N Engl J Med"},{"issue":"3","key":"1226_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/00005792-198005000-00003","volume":"59","author":"PG Ramsey","year":"1980","unstructured":"Ramsey PG, Rubin RH, Tolkoff-Rubin NE, Cosimi AB, Russell PS, Greene R. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine (Baltimore). 1980;59(3):206\u201322.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1226_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00001432-200208000-00002","volume":"15","author":"MG Ison","year":"2002","unstructured":"Ison MG, Hayden FG. Viral infections in immunocompromised patients: what\u2019s new with respiratory viruses? Curr Opin Infect Dis. 2002;15(4):355\u201367.","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"1226_CR24","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1002\/ajh.25851","volume":"95","author":"B Koffman","year":"2020","unstructured":"\u2022 Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, et al. Management of CLL patients early in the COVID-19 pandemic: an international survey of CLL experts. Am J Hematol. 2020;95(8):E199\u2013e203.\u00a0This survey (April 2020) conducted the American Society of Hematology (ASH) to provide an online resource for frequently asked questions about care of patients with COVID-19 in the setting of hematologic malignancies including CLL.","journal-title":"Am J Hematol"},{"issue":"2","key":"1226_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106\u201311.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1226_CR26","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"L Scarf\u00f2","year":"2020","unstructured":"Scarf\u00f2 L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354\u201363.","journal-title":"Leukemia."},{"issue":"10","key":"1226_CR27","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood.2020006965","volume":"136","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134\u201343.","journal-title":"Blood."},{"key":"1226_CR28","unstructured":"\u2022 The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19. Lancet Oncol. 2020;21(5):622\u20134. The UK Coronavirus Cancer Monitoring Project (UKCCMP) aims to collect, analyse, and disseminate in real time data from the UK cancer centres about SARS-CoV-2 infection rates in patients with cancer, and their outcomes in terms of COVID-19. This enables physicians to gain crucial insights to inform decision making."},{"issue":"10241","key":"1226_CR29","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907\u201318.","journal-title":"Lancet."},{"issue":"35","key":"1226_CR30","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.1200\/JCO.2008.16.4681","volume":"26","author":"A Gardner","year":"2008","unstructured":"Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26(35):5684\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1226_CR31","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/sj.leu.2404440","volume":"20","author":"EJ Bow","year":"2006","unstructured":"Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20(12):2087\u201392.","journal-title":"Leukemia."},{"issue":"4","key":"1226_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/ajcp\/72.4.617","volume":"72","author":"SY Cho","year":"1979","unstructured":"Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol. 1979;72(4):617\u201321.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"1226_CR33","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56\u201393.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1226_CR34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijantimicag.2007.07.026","volume":"30","author":"A Madureira","year":"2007","unstructured":"Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents. 2007;30(6):551\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1226_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1086\/597089","volume":"48","author":"NC Issa","year":"2009","unstructured":"Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48(6):772\u201386.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1226_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/07357909709039721","volume":"15","author":"CP Escalante","year":"1997","unstructured":"Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Investig. 1997;15(3):237\u201342.","journal-title":"Cancer Investig"},{"key":"1226_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/jama.1965.03080190138035","volume":"192","author":"DM Weber","year":"1965","unstructured":"Weber DM, Pellecchia JA. Varicella pneumonia: study of prevalence in adult men. JAMA. 1965;192:572\u20133.","journal-title":"JAMA."},{"issue":"1","key":"1226_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12879-017-2301-4","volume":"17","author":"P Auguste","year":"2017","unstructured":"Auguste P, Tsertsvadze A, Pink J, Court R, McCarthy N, Sutcliffe P, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):200.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"1226_CR39","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.5588\/ijtld.18.0743","volume":"23","author":"P Auguste","year":"2019","unstructured":"Auguste P, Madan J, Tsertsvadze A, Court R, McCarthy N, Sutcliffe P, et al. Identifying latent tuberculosis in high-risk populations: systematic review and meta-analysis of test accuracy. Int J Tuberc Lung Dis. 2019;23(11):1178\u201390.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1226_CR40","doi-asserted-by":"publisher","first-page":"m549","DOI":"10.1136\/bmj.m549","volume":"368","author":"JR Campbell","year":"2020","unstructured":"Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549.","journal-title":"BMJ."},{"issue":"4","key":"1226_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ccm.2019.07.003","volume":"40","author":"MS Godfrey","year":"2019","unstructured":"Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-\u03b1 and beyond. Clin Chest Med. 2019;40(4):721\u201339.","journal-title":"Clin Chest Med"},{"issue":"2","key":"1226_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.immuni.2008.06.011","volume":"29","author":"H Clay","year":"2008","unstructured":"Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008;29(2):283\u201394.","journal-title":"Immunity."},{"issue":"2","key":"1226_CR43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.27271","volume":"62","author":"PL Lin","year":"2010","unstructured":"Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, Fuhrman C, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 2010;62(2):340\u201350.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1226_CR44","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u00a0years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362.","journal-title":"Ann Rheum Dis"},{"key":"1226_CR45","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24 Suppl 2","author":"M Mikulska","year":"2018","unstructured":"\u2022\u2022 Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fern\u00e1ndez-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24 Suppl 2:S71\u2013s82.\u00a0This review from the group for infections in compromised hosts, analyze the safety of targeted and biological therapies from an Infectious Diseases perspective, and suggests preventive recommendations.","journal-title":"Clin Microbiol Infect"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01226-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01226-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01226-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:38:49Z","timestamp":1744198729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01226-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01226-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"15 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}